Multiple clinical trials are actively investigating the role of targeting homologous recombination deficiency (HRD) in ES via CHK1 (ClinicalTrials.gov identifier: NCT05275426) and PARP inhibition (ClinicalTrials.gov identifier: NCT01858168, NCT04901702). Here, PARP1 is linked to Ewing sarcoma.